Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection

Khursheed Muzammil,Mohammad Hosseini Hooshiar,Shirin Varmazyar,Thabit Moath Omar,Manal Morad Karim,Sadeq Aadi,Shaylan Kalavi,Saman Yasamineh
DOI: https://doi.org/10.1186/s12934-024-02355-8
IF: 6.352
2024-03-27
Microbial Cell Factories
Abstract:Cellular lipid membranes serve as the primary barrier preventing viral infection of the host cell and provide viruses with a critical initial point of contact. Occasionally, viruses can utilize lipids as viral receptors. Viruses depend significantly on lipid rafts for infection at virtually every stage of their life cycle. The pivotal role that proprotein convertase subtilisin/kexin Type 9 (PCSK9) plays in cholesterol homeostasis and atherosclerosis, primarily by post-transcriptionally regulating hepatic low-density lipoprotein receptor (LDLR) and promoting its lysosomal degradation, has garnered increasing interest. Conversely, using therapeutic, fully humanized antibodies to block PCSK9 leads to a significant reduction in high LDL cholesterol (LDL-C) levels. The Food and Drug Administration (FDA) has approved PCSK9 inhibitors, including inclisiran (Leqvio®), alirocumab (Praluent), and evolocumab (Repatha). At present, active immunization strategies targeting PCSK9 present a compelling substitute for passive immunization through the administration of antibodies. In addition to the current inquiry into the potential therapeutic application of PCSK9 inhibition in human immunodeficiency virus (HIV)-infected patients for hyperlipidemia associated with HIV and antiretroviral therapy (ART), preclinical research suggests that PCSK9 may also play a role in inhibiting hepatitis C virus (HCV) replication. Furthermore, PCSK9 inhibition has been suggested to protect against dengue virus (DENV) potentially and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses. Recent evidence regarding the impact of PCSK9 on a variety of viral infections, including HCV, HIV, DENV, and SARS-CoV-2, is examined in this article. As a result, PCSK9 inhibitors and vaccines may serve as viable host therapies for viral infections, as our research indicates that PCSK9 is significantly involved in the pathogenesis of viral infections.
biotechnology & applied microbiology
What problem does this paper attempt to address?
The problem this paper attempts to address is to explore the various aspects of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid regulation and how different viral infections affect the lipid regulatory function of PCSK9. The study finds that PCSK9 not only plays a key role in cholesterol homeostasis but may also be involved in the pathogenesis of various viral infections. Therefore, the paper aims to elucidate the specific role of PCSK9 in the viral lifecycle and to explore whether targeting PCSK9 through vaccines and inhibitors could be an effective strategy for treating viral infections. Specifically, the paper focuses on the following aspects: 1. **The role of PCSK9 in cholesterol metabolism**: PCSK9 regulates cholesterol levels by degrading low-density lipoprotein receptors (LDLR), which is significant in cardiovascular diseases. 2. **The role of PCSK9 in viral infections**: Studies have found that PCSK9 may be involved in the infection processes of various viruses (such as hepatitis C virus, human immunodeficiency virus, dengue virus, and the novel coronavirus), particularly in the entry and replication of viruses in host cells. 3. **Potential therapeutic applications of PCSK9 inhibitors**: By inhibiting PCSK9, the degradation of LDLR can be reduced, thereby lowering the levels of low-density lipoprotein cholesterol (LDL-C) in the blood. Additionally, PCSK9 inhibitors may have antiviral effects against certain viral infections. 4. **Vaccine and drug development**: The study explores the possibility of preventing and treating viral infections by targeting PCSK9 through vaccines and drugs. In summary, this paper aims to comprehensively understand the multiple roles of PCSK9 in lipid metabolism and viral infections and to evaluate its potential as a therapeutic target.